john stankey and robert davis are prominent American corporate executives leading AT&T and Merck, respectively. As of October 1, 2026, there is no publicly documented direct business, family, or board relationship between them, despite their similar positions at major U.S. public companies.
In this context, “Robert Davis” most plausibly refers to Robert M. Davis, chairman and chief executive officer of pharmaceutical company Merck & Co., Inc. Official corporate records show John Stankey running telecommunications giant AT&T while Davis leads Merck, with their careers developing in different industries and organizations.
Who Are John Stankey and Robert Davis?
John Stankey and Robert M. Davis are both chairman-CEOs of large publicly traded U.S. corporations, but their professional backgrounds are quite different.
Stankey has spent essentially his entire career inside AT&T and its predecessor organizations. Davis built his career through Eli Lilly, Baxter and Merck before becoming Merck’s chief executive.
| Executive | Current company | Current position | Became CEO | Main industry |
|---|---|---|---|---|
| John Stankey | AT&T Inc. | Chairman and CEO | July 2020 | Telecommunications |
| Robert M. Davis | Merck & Co., Inc. | Chairman and CEO | July 2021 | Pharmaceuticals and healthcare |
AT&T’s official biography says Stankey has led the company as CEO and president since July 2020 and became chairman in February 2025. Merck says Davis became its CEO on July 1, 2021, and chairman on December 1, 2022.
Is There a Connection Between John Stankey and Robert Davis?
There is no verified direct professional relationship between John Stankey and Robert M. Davis in the current corporate records reviewed for this article.
Neither man’s current company board includes the other. AT&T lists Stankey as chairman and CEO alongside its independent directors, while Merck’s current board lists Davis and 12 other directors without Stankey.
Their companies also operate in fundamentally different markets. AT&T is centered on wireless, fiber and other connectivity services, while Merck develops pharmaceuticals, vaccines and animal-health products.
That does not mean the two executives have never attended the same large business conference, industry gathering or policy event. CEOs of companies of this scale often participate in overlapping corporate and economic forums. However, no reliable evidence found in the official biographies, current board rosters or recent company disclosures establishes a significant personal partnership, joint venture or shared corporate role between Stankey and Davis.
John Stankey’s Career at AT&T
John Stankey is one of the longest-serving senior executives associated with AT&T. He joined the company in 1985, giving him more than four decades of experience across telecommunications, technology and media.
Before becoming CEO, Stankey held a wide range of positions, including chief information officer, chief technology officer, CEO of AT&T Operations, CEO of AT&T Business Solutions, chief strategy officer, CEO of AT&T Entertainment Group, CEO of WarnerMedia and president and chief operating officer.
That unusually broad internal career gave him exposure to both AT&T’s traditional telecommunications infrastructure and its previous expansion into entertainment.
The AT&T strategy under Stankey
Stankey’s more recent leadership has been associated with sharpening AT&T’s focus around connectivity, particularly 5G wireless and fiber broadband.
AT&T reported full-year 2025 revenue of $125.6 billion, up from $122.3 billion in 2024. The company also reported more than one million AT&T Fiber net additions for the eighth consecutive year and more than 1.5 million postpaid phone net additions.
That strategy remained central in 2026. AT&T’s second-quarter results, released July 22, showed more than one million Advanced Connectivity customer additions across fiber, fixed wireless and postpaid phones. Stankey said the results reflected the company’s effort to build around its network assets.
In September 2026, AT&T again said its multi-year strategy remained focused on combining fiber and 5G while pursuing improved growth and shareholder returns.
John Stankey’s education
Stankey holds a Bachelor of Business Administration in finance from Loyola Marymount University and an MBA from UCLA, according to AT&T.
Robert M. Davis’s Career at Merck
Robert M. Davis took a different route to the top.
Before joining Merck, Davis spent 14 years at Eli Lilly and Company. He later worked at Baxter, where his positions included chief financial officer, treasurer, president of its renal business and president of the medical products business.
Davis joined Merck in 2014 as chief financial officer. His responsibilities expanded to include corporate strategy, business development, information technology, procurement and other global services.
He became Merck president in April 2021 and CEO on July 1, 2021. The company’s board elected him chairman effective December 1, 2022.
Merck’s strategy under Davis
Davis leads Merck at an important point in the pharmaceutical company’s development. The company is working to diversify its drug portfolio while continuing to invest heavily in research and development.
Merck generated $65.0 billion in 2025 revenue and spent approximately $15.8 billion on research and development, according to its company fact sheet.
During the second quarter of 2026, Merck reported worldwide sales of $16.6 billion. The company said growth was supported by oncology, animal health and newer product launches, while its full-year 2026 sales guidance stood at $66.3 billion to $67.3 billion at the time of the August results.
Davis has also emphasized acquisitions and external research as ways to strengthen Merck’s future product pipeline. Merck completed its acquisition of Terns Pharmaceuticals in May 2026, adding the investigational oncology drug TERN-701 to its development portfolio.
Robert Davis’s education
Davis has an unusually broad academic background for a pharmaceutical CEO. He earned:
- a bachelor’s degree in finance from Miami University
- an MBA from Northwestern University’s Kellogg School of Management
- a Juris Doctor from Northwestern University Pritzker School of Law
These qualifications are confirmed in Merck’s official executive biography.
Also Read: Greg Hayes and Robert Davis
John Stankey and Robert Davis: Leadership Comparison
The clearest connection between John Stankey and Robert Davis is not a direct relationship but their comparable positions in corporate America.
Both oversee companies with tens of billions of dollars in annual revenue. Both hold the combined roles of chairman and chief executive officer. Both are also managing businesses undergoing significant strategic change.
The similarities largely end there.
Stankey’s professional expertise was built within telecommunications, network infrastructure, technology and media. His current strategy revolves around fiber deployment, wireless services, convergence and customer connectivity.
Davis has worked primarily in pharmaceuticals, healthcare products, corporate finance and life sciences. His current challenges involve drug development, clinical pipelines, regulatory approvals, acquisitions and the long-term economics of pharmaceutical innovation.
Their responsibilities are therefore comparable in corporate scale but very different in practical substance.
How Their Companies Compare
AT&T is significantly larger than Merck when measured strictly by annual revenue, although revenue alone does not determine company value, profitability or executive responsibility.
AT&T reported $125.6 billion in 2025 revenue, while Merck reported $65.0 billion.
AT&T’s business depends heavily on recurring consumer and enterprise spending on wireless and broadband connectivity. Its capital requirements include enormous investments in network equipment, spectrum and fiber infrastructure.
Merck’s economics are different. Pharmaceutical companies spend heavily on research that may take years to produce an approved medicine. A relatively small number of successful medicines can then account for large portions of sales, creating different scientific, regulatory and patent-related risks.
This industry difference is important when comparing Stankey and Davis. Similar titles do not mean they manage similar businesses.
John Stankey and Robert Davis Compensation
Public-company filings provide reliable information about annual executive compensation, although executive compensation should not be confused with personal net worth.
AT&T’s 2026 proxy statement reported $29,906,872 in total 2025 compensation for John Stankey. The total included a $2.4 million salary, approximately $19.5 million in stock awards, $6.272 million in non-equity incentive compensation and other reported components.
Merck’s 2026 proxy reported $20,797,845 in total 2025 compensation for Robert M. Davis. The figure included approximately $1.65 million in salary, $12.10 million in stock awards, $3.38 million in option awards and $2.33 million in non-equity incentive compensation, along with pension-related and other compensation.
| Executive | Reported 2025 total compensation |
|---|---|
| John Stankey | $29.91 million |
| Robert M. Davis | $20.80 million |
These are SEC-disclosed annual compensation figures, not estimates of how much money either executive personally owns. Reliable net worth calculations would require information about assets, liabilities, private investments, property and other holdings that public-company filings generally do not fully disclose.
For that reason, highly specific online estimates of either man’s net worth should be treated cautiously unless they explain their methodology and rely on verifiable ownership records.
Are John Stankey and Robert Davis on Each Other’s Boards?
No. Current board records do not show Robert Davis serving as an AT&T director or John Stankey serving as a Merck director.
AT&T’s board is chaired by Stankey. Merck’s board is chaired by Davis, and Merck’s directors elected in May 2026 included Davis, Douglas M. Baker Jr., Mary Ellen Coe, Pamela J. Craig, Thomas H. Glocer, Surendralal L. Karsanbhai, Risa J. Lavizzo-Mourey, Stephen L. Mayo, Paul B. Rothman, Patricia F. Russo, Christine E. Seidman, Inge G. Thulin and Kathy J. Warden.
This is useful because board membership is one of the most common explanations when searches pair two unrelated senior executives. In this case, it does not explain the combination.
Are John Stankey and Robert Davis Related?
There is no credible public evidence identifying John Stankey and Robert M. Davis as relatives.
Their official biographies describe separate career histories, educational backgrounds and corporate affiliations. No family relationship between the two is identified in the authoritative corporate records reviewed for this article.
Claims suggesting otherwise would therefore require evidence beyond simply seeing their names appear together in executive lists, search results or CEO databases.
Why Do John Stankey and Robert Davis Appear Together in Searches?
One likely explanation is that both men belong to the same broad category of executives: leaders of major U.S. public companies.
Search engines often connect names through lists covering chief executives, executive compensation, large corporations or business leadership. Stankey and Davis can consequently appear near each other in datasets without having a personal or professional relationship.
The important distinction is between co-occurrence and connection. Two people appearing in the same CEO list does not establish that they have worked together, invested together, served on the same board or have a personal relationship.
For readers researching john stankey and robert davis, the strongest verified answer is therefore that they are separate corporate leaders whose primary connection is their comparable status as chairman-CEOs of major U.S. companies.
FAQ
Who are John Stankey and Robert Davis?
John Stankey is chairman and CEO of AT&T Inc. Robert M. Davis is chairman and CEO of Merck & Co., Inc. Both lead large U.S. public companies, but in different industries.
Do John Stankey and Robert Davis work together?
No significant direct working relationship is identified in their current official corporate biographies, executive teams or board memberships. Stankey leads AT&T while Davis leads Merck.
Are John Stankey and Robert Davis related?
No credible public evidence reviewed for this article identifies them as relatives. They have separate professional histories and corporate affiliations.
Is Robert Davis on the AT&T board?
No. AT&T’s current board information does not list Robert M. Davis as a director.
Is John Stankey on the Merck board?
No. Merck’s current board roster does not include John Stankey. Robert M. Davis is Merck’s chairman and CEO.
How much were John Stankey and Robert Davis paid in 2025?
According to their companies’ 2026 proxy statements, Stankey’s reported 2025 total compensation was approximately $29.91 million, while Davis’s was approximately $20.80 million. These figures represent annual executive compensation, not personal net worth.
Also Read: Cate Blanchett and Robert Davis
